Key takeaways:
- Exogenous testosterone, whether from a gel, an injection, or a pellet, suppresses the pituitary hormones LH and FSH that sperm production depends on, and can collapse intratesticular testosterone, the concentration inside the testes, by more than 80 percent even while blood testosterone reads normal or high (Al Hashimi et al., Asian Journal of Andrology, 2025).
- In a study of 4,400 men evaluated at a real male infertility clinic, 59 were taking prescribed testosterone, and 88.4 percent of them were azoospermic, meaning no measurable sperm in their semen, while they were on it (Samplaski et al., Fertility and Sterility, 2014).
- Testosterone prescribing has grown fastest in men in their twenties and thirties, the exact age group most likely to still want children, with an 86 percent increase among men aged 25 to 34 between 2018 and 2022 (Selinger and Thallapureddy, PLOS ONE, 2024).
Testosterone therapy gets sold, culturally and sometimes clinically, as a return to virility: more energy, more muscle, more libido, more of whatever "low T" is assumed to have taken away. What rarely comes up in that conversation is that testosterone therapy is also one of the most reliable ways to stop sperm production almost entirely, and it does it quietly. Blood testosterone goes up. Semen volume does not obviously change. A man can feel better in every way that matters to him day to day while his sperm count is falling toward zero, and by the time anyone checks, there may not be a clean baseline left to compare against.
This is not a fringe risk or a rare side effect buried in fine print. It is the expected, mechanistically predictable result of how exogenous testosterone interacts with the hormonal system that controls sperm production, and it happens to real men, on real prescriptions, written by real doctors, more often than most people assume. This article covers what actually happens in the body, how often it happens in practice, and who is most exposed to the risk without realizing it.
What actually happens to sperm production on testosterone therapy?
It shuts down, in most men, almost completely. Sperm are not made in response to the testosterone circulating in your bloodstream, the number that shows up on a standard lab test. They are made in response to testosterone concentrated locally inside the testes, at a level that is normally 50 to 100 times higher than what is circulating in blood (Al Hashimi et al., Asian Journal of Andrology, 2025). That local concentration depends on a signal from the brain, not on how much testosterone is floating around elsewhere in the body. When a man takes testosterone from an outside source, gel, injection, or pellet, his brain detects the elevated blood level and responds by shutting off the very signal that tells the testes to keep producing testosterone locally, which is also the signal that keeps sperm production running.
Why does adding testosterone from outside shut down the system inside?
Because the brain and testes run on a feedback loop, and exogenous testosterone breaks it in the same direction every time. The hypothalamus, a small structure at the base of the brain, releases a hormone in pulses that tells the pituitary gland to release two more hormones, LH and FSH. LH travels to specialized cells in the testes called Leydig cells and tells them to produce testosterone locally, at that 50 to 100 times higher concentration. FSH travels to a different set of cells, Sertoli cells, that support and nurture developing sperm. Together, LH and FSH are what keep spermatogenesis, the roughly 72 day process of producing mature sperm, running at all.
The brain does not distinguish between testosterone your testes made and testosterone that came from a syringe or a tube of gel. It only sees the total level in your blood, and when that level rises, the hypothalamus and pituitary read it as a signal to ease off, the same negative feedback loop that normally keeps testosterone in a stable range. LH and FSH drop, in many men to levels so low they are barely detectable (Al Hashimi et al., Asian Journal of Andrology, 2025). Without the LH signal, the local, high-concentration testosterone inside the testes collapses, even though the number on a blood test looks fine or even high. A decline in intratesticular testosterone of more than 80 percent from its normal level is enough to derail spermatogenesis (Al Hashimi et al., Asian Journal of Andrology, 2025; Desai et al., Therapeutic Advances in Urology, 2022). Without the FSH signal, the Sertoli cells that support developing sperm lose part of what keeps them functioning. The result is a system that looks fine from the outside, a normal or high testosterone reading, while the actual sperm production line has been told to stop.
How common is TRT-induced infertility, really?
More common than the phrase "possible side effect" suggests. The clearest real-world number comes from a study of 4,400 men evaluated at a male infertility clinic in Canada. Only 59 of them, 1.3 percent, reported taking exogenous testosterone, prescribed by a range of doctors including endocrinologists, general practitioners, urologists, and gynecologists. But among those 59 men, 88.4 percent were azoospermic, meaning their semen contained no measurable sperm at all, while they were taking it (Samplaski et al., Fertility and Sterility, 2014). That is not a small or borderline effect. It is close to the entire group.
Controlled research points the same direction even more starkly. In a World Health Organization multinational study of 670 healthy volunteer men given weekly testosterone injections, 97 percent suppressed to either azoospermia or severe oligozoospermia, a sperm concentration low enough to functionally block natural conception, regardless of the men's ethnic background (World Health Organization Task Force, International Journal of Andrology, 1995). That study used testosterone as an experimental contraceptive, which is a different intent than treating low testosterone, but the mechanism is identical, and the real-world clinic data above shows the same near-total suppression happening in men on ordinary clinical prescriptions, not experimental protocols.
What makes this more than a historical curiosity is who is actually being prescribed testosterone now. A 2024 analysis of prescription drug monitoring data across the United States found that testosterone prescribing rose 27 percent overall between 2018 and 2022, but the growth was fastest in exactly the men who are most likely to still be building a family: an 86 percent increase among men aged 25 to 34, and a 120 percent increase among men under 24 (Selinger and Thallapureddy, PLOS ONE, 2024). Testosterone therapy used to be discussed mostly as an issue for men in their 50s and 60s. The prescribing data says the fastest-growing group is a full generation younger.
Is everyone on TRT affected the same way?
No, and this is one of the genuinely uncertain parts of the picture. In the WHO study above, Asian men suppressed to azoospermia somewhat more slowly at first than non-Asian men, though both groups converged on similarly high suppression rates by six to twelve months (World Health Organization Task Force, International Journal of Andrology, 1995). Dose, duration of use, a man's baseline testicular reserve, and individual variation in how sensitive his hypothalamus and pituitary are to feedback all plausibly affect how fast and how completely a given man suppresses. What the evidence does not currently support is the idea that a "low" or conservative testosterone dose is somehow safe for fertility. The Samplaski clinic data reflects ordinary prescriptions written for symptoms like low energy or low libido, not experimental high-dose protocols, and it still found suppression in the vast majority of men. There is no well established dose or delivery method, gel, injection, or pellet, that reliably avoids this effect once blood testosterone reaches a typical treatment target.
Does this mean the infertility is permanent?
For most men, no, but it is not instant either. Among the men in the Samplaski clinic study who stopped testosterone and had no other identified cause of azoospermia, 65 percent had measurable sperm production back within six months (Samplaski et al., Fertility and Sterility, 2014). A separate analysis pooling data from 1,549 men across 30 studies found that after stopping testosterone-based regimens, the majority of men recovered sperm concentration above key thresholds within a predictable window, with most recovery happening within the first year and the great majority of men recovering by two years (Liu et al., Lancet, 2006). Older reviews describe a similar pattern in plain terms: most men see a return of normal sperm production within about a year of stopping (Crosnoe et al., Translational Andrology and Urology, 2013). Recovery is real for most men, but "most" is not "all," and the honest caveat is that a smaller group of men, particularly those on testosterone for a long time or with lower testicular reserve to begin with, recover more slowly or incompletely. The full evidence on recovery timelines, and what can be done to speed it along, is its own topic, worth its own dedicated look rather than a few paragraphs here.
What we're more skeptical about
A pattern we see discussed online, and sometimes recommended informally, is trying to counteract TRT's effect on fertility by adding antioxidant supplements, CoQ10, L-carnitine, or similar, while staying on testosterone therapy. That does not address the actual mechanism. The problem is not oxidative damage that an antioxidant could offset, it is that the LH and FSH signal driving spermatogenesis has been switched off. No supplement restores a pituitary signal that exogenous testosterone is actively suppressing. We are also skeptical of the informal reassurance some men report hearing, that a "low" or "physiologic" TRT dose will not meaningfully affect fertility. The evidence above, from real clinic prescriptions rather than experimental high-dose protocols, does not support that claim. If preserving fertility while treating low testosterone symptoms is the actual goal, the honest options are testing before starting, choosing an alternative that does not suppress the axis the same way, or planning for sperm banking, not hoping a supplement or a lower dose will quietly solve it.
How does this fit into the bigger picture?
This is why testing before the first dose matters more than it usually gets treated. A baseline semen analysis and hormone panel, taken before starting testosterone, is the only way to later tell whether a fertility problem was already present or was caused by the treatment; our guide to what to test before starting TRT walks through exactly what to check and why. For men who need the benefits of raised testosterone but still want to preserve fertility, alternatives like enclomiphene, clomiphene, and hCG work by raising the body's own LH and FSH signal instead of replacing testosterone from outside, which is why they do not shut down sperm production the same way; we cover how that works and who it fits in our enclomiphene article. And because testosterone, LH, and FSH tell a connected story, not three separate numbers, it is worth reading a testosterone result together with the rest of the panel rather than in isolation; our testosterone and fertility article and LH article cover how to read them together.
Our take
We know that exogenous testosterone suppresses the LH and FSH signal that sperm production depends on, and that this is not a rare or unusual reaction, it is close to the expected outcome, seen in roughly 9 out of 10 men in the best real-world clinic data available. We know that testosterone prescribing is rising fastest in men in their twenties and thirties, which means more men of reproductive age are being exposed to this risk than at any point in the recent past, often without a clear conversation about fertility before the first dose. We also know that recovery is realistic for most men once testosterone is stopped, which is genuinely reassuring, but it depends on stopping, on time, and in some cases on the right monitoring, not on hoping the effect will not apply to you.
What we do not know as precisely is exactly how an individual man's dose, duration, age, and baseline testicular reserve combine to predict his personal risk and recovery timeline, since most of the strongest evidence comes from population averages rather than a tool that predicts one man's outcome in advance. The practical answer is not to avoid testosterone therapy if you genuinely need it. It is to know your numbers, semen parameters and hormones, before you start, so that "before" and "after" mean something.
FAQ
Can testosterone replacement therapy (TRT) cause infertility?
Yes. Exogenous testosterone suppresses the pituitary hormones LH and FSH that drive sperm production, and in a study of 4,400 men at a male infertility clinic, 88.4 percent of the men taking prescribed testosterone were azoospermic, meaning they had no measurable sperm, while on it (Samplaski et al., Fertility and Sterility, 2014).
How long does it take for TRT to affect sperm count?
In controlled studies using weekly testosterone injections, most men suppressed to azoospermia or severe oligozoospermia within about six months, with the effect building over that window rather than appearing instantly (World Health Organization Task Force, International Journal of Andrology, 1995).
Does a low dose of testosterone still affect fertility?
Real-world clinic data does not support the idea that ordinary treatment doses are safe for fertility. The 88.4 percent azoospermia rate reported by Samplaski and colleagues came from men on standard clinical prescriptions for symptoms like low energy or low libido, not experimental high-dose protocols (Samplaski et al., Fertility and Sterility, 2014).
Is TRT-induced infertility permanent?
Usually not. In the same clinic study, 65 percent of men with no other identified cause of azoospermia recovered measurable sperm production within six months of stopping testosterone, and larger recovery analyses show most men recovering within a year to two years (Samplaski et al., Fertility and Sterility, 2014; Liu et al., Lancet, 2006).
What should I test before starting testosterone therapy if I want children later?
A baseline semen analysis and a hormone panel covering testosterone, LH, and FSH, taken before the first dose, so that any later change can be measured against a real starting point rather than assumed.
References
- Al Hashimi M, Pinggera GM, Shah R, Agarwal A. Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids. Asian Journal of Andrology. 2025;27(3):330-341. https://pmc.ncbi.nlm.nih.gov/articles/PMC12112917/
- Desai A, Yassin M, Cayetano A, Tharakan T, Jayasena CN, Minhas S. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology. 2022;14:17562872221105017. https://pmc.ncbi.nlm.nih.gov/articles/PMC9243576/
- Samplaski MK, Loai Y, Wong K, Lo KC, Grober ED, Jarvi KA. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertility and Sterility. 2014;101(1):64-69. https://pubmed.ncbi.nlm.nih.gov/24094422/
- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. International Journal of Andrology. 1995;18(3):157-165. https://pubmed.ncbi.nlm.nih.gov/7558380/
- Selinger S, Thallapureddy A. Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022. PLOS ONE. 2024;19(8):e0309160. https://doi.org/10.1371/journal.pone.0309160
- Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420. https://pubmed.ncbi.nlm.nih.gov/16650651/
- Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology. 2013;2(2):106-113. https://tau.amegroups.org/article/view/2249
Curious what your own numbers look like before or during testosterone therapy? SwimScore Complete measures concentration, motility, morphology, DNA fragmentation, and a full hormone panel together from home, processed in the same CLIA-certified labs used by fertility clinics, so you have a real baseline to compare against.
Fertility clinics and urology practices: if patients are starting or already on testosterone therapy, a fast, complete baseline panel makes the fertility conversation concrete instead of theoretical. See how SwimScore works with clinics on our clinic page.
This article is for general education and is not medical advice. Decisions about starting, continuing, or stopping testosterone therapy, and about preserving fertility, should be made with a urologist, endocrinologist, or fertility specialist who knows your full history.
SwimScore uses CLIA-certified labs for all semen analysis and hormone testing, assessed against WHO 6th Edition clinical thresholds.
